Tom Powles: SUNNIFORCAST at ESMO24

Tom Powles shared a post on X:

“SUNNIFORCAST at ESMO24 ipi/nivo vs VEGF based therapy in advanced non-clear cell renal cancer. + ve 12 month OS,OS HR 0.86, RR but -ve PFS.

Uncertainty around papillary subgroup and mixed control arm.

But PD-1 based therapy looks like the backbone of future therapy. PD-L1 biomarker?”

Source: Tom Powles/X

More posts featuring Tom Powles on oncodaily.com

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.

His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.